Drugs News and Research

RSS

News outlets examine global response to HIV/AIDS ahead of World AIDS Day

The Associated Press explores how PEPFAR funds are being used to help connect patients living with the disease to treatment, provide support for families and educate the public about the disease in Vietnam.

1 Dec 2009

New Medicare advantage plans for affordable and quality health care

HealthPlus of Michigan today announced the launch of two new HealthPlus MedicarePlus plans designed for Medicare-eligible people looking for affordable benefit choices and convenient access to quality health care.

1 Dec 2009

Clinical interventions may help cocaine abusers from using drugs and prevent relapse

When asked to inhibit their response to a "cocaine-cues" video, active cocaine abusers were, on average, able to suppress activity in brain regions linked to drug craving, according to a new study at the U.S. Department of Energy's Brookhaven National Laboratory. The results, to be published in an upcoming issue of NeuroImage, suggest that clinical interventions designed to strengthen these inhibitory responses could help cocaine abusers stop using drugs and avoid relapse.

30 Nov 2009

Details of the policies inside the Senate's health overhaul bill

Hot-button provisions in the Senate health Bill, such as the public option, cost controls and subsidies to expand coverage continue to get a lot of attention, while some interesting details have gone with little notice.

30 Nov 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Pharmacists could play important role in reform

Pharmacists may play an important role in the health care system by filling in health care gaps and advising patients, according to a series of articles in The Los Angeles Times, which reports on one clinical pharmacist Steven Chen and the "Patient Safety and Clinical Pharmacy Services Collaborative, a national project under the Health Resources and Services Administration that is working to integrate clinical pharmacy services into the care of patients with chronic diseases.

30 Nov 2009

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Medicare prescription drug plan premiums to average 11 percent rise in 2010

Premiums for Medicare Part D plans will rise an average of 11 percent next year, the Milwaukee Journal Sentinel reports. The cost for all Medicare prescription plans has increased 50 percent nationally since 2006.

30 Nov 2009

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Acsys Interactive's recommendations to the FDA on social media in the healthcare industry

At the invitation of the Food and Drug Administration, Stan Valencis, President of Acsys Interactive, recently presented a series of recommendations to help shape the government's policy towards the promotion of prescription drugs, biologics and medical devices using the Internet and social media tools. As a leader in providing digital marketing and interactive strategies to healthcare systems, hospitals, device manufacturers and pharmaceutical companies, Acsys Interactive was selected by the FDA to provide its uniquely qualified perspective and experience.

30 Nov 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Study provides new insight into the mechanism of bacterial invasion protein

Spoiled meat is one of the sources for Listeria infections leading to listeriosis. Pregnant women, newborns and immune compromised people are susceptible for a severe progression of this disease. Firstly, the pathogen breaches the intestinal barrier and thus enters the body. The key for further spreading is the invasion protein internalin B that is located on the bacterial surface.

30 Nov 2009

Novel initiative to improve NMR structure determination

In structural biology, the only technique available to predict the three dimensional structure of large complex molecules in solution, such as proteins and DNA, is NMR spectroscopy. To catalyze improvements in the techniques behind these predictions, the "eNMR" project has launched a new initiative. In September's Nature Methods the project issued an invitation to the entire biomolecular Nuclear Magnetic Resonance community to participate in a large scale test of modern computing algorithms.

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

University HealthSystem Consortium signs agreement with ECRI Institute

The University HealthSystem Consortium (UHC) today announced that it has signed an agreement with ECRI Institute® in Plymouth Meeting, Pa, to offer its academic medical center members special pricing on ECRI's library of current technology research.

30 Nov 2009

Prevalence of osteoarthritis continues to rise; OA expenses nearly 100% higher for women than men

Osteoarthritis (OA), a highly prevalent disease, raised aggregate annual medical care expenditures in the U.S. by $185.5 billion according to researchers from Stony Brook University. Insurers footed $149.4 billion of the total medical spend and out-of-pocket (OOP) expenditures were $36.1 billion (2007 dollars). Results of the cost analysis study are published in the December issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

30 Nov 2009

Study on placebo effect

A short time ago, Swedish scientists published a paper suggesting the existence of a genetic disposition to respond to placebo, thus giving rise to debate in the media about a possible "placebo gene." In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[46]: 751-5), Matthias Breidert and Karl Hofbauer summarize the most recent data about placebos.

28 Nov 2009

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, which have functional groups on the walls that allows for conjugation with cancer drugs, was developed in partnership with the Indian Institute of Kanpur (ITT). The conjugated carbon nanotubes serves as a drug delivery vehicle with the ability to target the cancer site which has the potential to increase the drug efficacy.

28 Nov 2009